Anti-KIF26A monoclonal antibody

Pre-made anti-KIF26A monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research

Target products collectionGo to KIF26A/KIF26A products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-IP2563-Ab-1/ GM-Tg-hg-IP2563-Ab-2Anti-Human KIF26A monoclonal antibodyHuman
GM-Tg-rg-IP2563-Ab-1/ GM-Tg-rg-IP2563-Ab-2Anti-Rat KIF26A monoclonal antibodyRat
GM-Tg-mg-IP2563-Ab-1/ GM-Tg-mg-IP2563-Ab-2Anti-Mouse KIF26A monoclonal antibodyMouse
GM-Tg-cynog-IP2563-Ab-1/ GM-Tg-cynog-IP2563-Ab-2Anti-Cynomolgus/ Rhesus macaque KIF26A monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-IP2563-Ab-1/ GM-Tg-felg-IP2563-Ab-2Anti-Feline KIF26A monoclonal antibodyFeline
GM-Tg-cang-IP2563-Ab-1/ GM-Tg-cang-IP2563-Ab-2Anti-Canine KIF26A monoclonal antibodyCanine
GM-Tg-bovg-IP2563-Ab-1/ GM-Tg-bovg-IP2563-Ab-2Anti-Bovine KIF26A monoclonal antibodyBovine
GM-Tg-equg-IP2563-Ab-1/ GM-Tg-equg-IP2563-Ab-2Anti-Equine KIF26A monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-IP2563-Ab-1/ GM-Tg-hg-IP2563-Ab-2; GM-Tg-rg-IP2563-Ab-1/ GM-Tg-rg-IP2563-Ab-2;
GM-Tg-mg-IP2563-Ab-1/ GM-Tg-mg-IP2563-Ab-2; GM-Tg-cynog-IP2563-Ab-1/ GM-Tg-cynog-IP2563-Ab-2;
GM-Tg-felg-IP2563-Ab-1/ GM-Tg-felg-IP2563-Ab-2; GM-Tg-cang-IP2563-Ab-1/ GM-Tg-cang-IP2563-Ab-2;
GM-Tg-bovg-IP2563-Ab-1/ GM-Tg-bovg-IP2563-Ab-2; GM-Tg-equg-IP2563-Ab-1/ GM-Tg-equg-IP2563-Ab-2
Products NameAnti-KIF26A monoclonal antibody
Formatmab
Target NameKIF26A
Protein Sub-locationIntrocelluar Protein
Category of antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected.
TagFc
Products descriptionPre-made anti-KIF26A monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-IP2563-Ag-1Recombinant multi-species KI26A/ KIF26A protein


    Target information

    Target IDGM-IP2563
    Target NameKIF26A
    Gene ID26153,668303,314473,702237,490875,101086658,100337486,100060810
    Gene Symbol and SynonymsCDCBM11,KIF26A,mKIAA1236
    Uniprot AccessionQ9ULI4
    Uniprot Entry NameKI26A_HUMAN
    Protein Sub-locationIntrocelluar Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000066735
    Target ClassificationN/A

    The target: KIF26A, gene name: KIF26A, also named as . Predicted to enable microtubule binding activity and microtubule motor activity. Predicted to be involved in enteric nervous system development; negative regulation of signal transduction; and regulation of cell growth by extracellular stimulus. Predicted to be located in cytosol. Predicted to be part of kinesin complex. Predicted to be active in microtubule. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.